Company focusing on giving clinicians with tools for leveraging proactive, value-based healthcare solutions, QHSLab Inc (OTCMKTS:USAQ), confirmed on fresh $90 million annual addressable market for its latest product, the Allergy Quick Test, branded AllergiQT.
On Tuesday, USAQ stock ended flat at $0.5150 with more than 8.3K shares, compared to its average volume of 1.1K shares. The stock moved within a range of $0.5150 – 0.5150 after opening trading at $0.30.
New $90 million annual addressable market for QHSLab’s latest product, the Allergy Quick Test, branded AllergiQT™.
Data shows an incredible opportunity for the latest allergy skin test device, the AllergiQT, a simple in office allergy test. This test is put on forearms, avoiding any drawing of blood, and demonstrating results in less than 15 minutes.
There are about 30,699 family medicine, pediatrician as well as non-allergy specialist physicians in May 2022. Lab tests are pricey ranging from $220 to over $500. The AllergiQT – Quick Test will cost insurance firms less than $100 per test and gets the reimbursement for doing the test without a laboratory.
The Quick Test gives allergen screening as well as for the most common allergens. There are more than 250,000 independent primary care physicians in US but over sixty million allergy suffering patients every year. This shows that the addressable market for QHSLab’s allergy product line is even much larger than current data suggests.
Troy Grogan, President, and CEO at QHSLab, Inc said that this is true value-based care, reducing healthcare costs as well as giving information for helping improve patient outcomes.
“This is true value-based care, lowering healthcare costs and providing information needed to help improve patient outcomes.” states Troy Grogan, President and CEO at QHSLab, Inc.
USAQ stock is trading above the 10-Day and 20-Day Moving averages of $0.4925 and $0.4895 respectively. However, the stock is trading below the 200-Day moving average of $0.6668.